Iovance Biotherapeutics opened lower at $7.91, compared with its previous close of $8.09. In the last trading session, the stock traded between $7.60 and $7.92. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Iovance Biotherapeutics is now worth
$ 32.45
Resulting in a loss of
$ 67.55 (67.55%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-0.46 (-5.74%)
Day High
$7.92
Day Low
$7.60
Day Open
$7.91
Prev Close
$8.09
Volume
92,49,959
1W Return
-12.64%
1M Return
-47.60%
3M Return
17.59%
6M Return
106.11%
1Y Return
187.77%
Market Cap ($ Mn)
3,528
PE Ratio
-
PB Ratio
4.94
PEG Ratio
-
ROE
-54.64%
ROCE
-50.87%
EPS (TTM)
$-0.05
1 Week
-12.64%
1 Month
-47.60%
3 Months
17.59%
6 Months
106.11%
9 Months
193.31%
Levi & Korsinsky probes Iovance Biotherapeutics over trial claims
Iovance Biotherapeutics faces a new securities fraud probe from Levi & Korsinsky. Stock dropped 35.45% to $9.56 per share on October 29, 2026. Investigation focuses on misleading statements about lifileucel Phase 2 trial results. Levi & Korsinsky joins Pomerantz LLP in pursuing potential class action claims.
TodayBarclays maintains Overweight on Iovance Biotherapeutics, raises target to $19
Barclays raised Iovance Biotherapeutics' price target to $19. Previous price target was set at $18. Analyst Etzer Darout maintained an Overweight rating. The update reflects a $1 increase in the valuation forecast.
6 days agoIovance Biotherapeutics affirms FY26 sales guidance of $410M-$420M
Iovance Biotherapeutics affirmed FY26 sales guidance of $410.000 million-$420.000 million. The guidance range remains unchanged from prior disclosures. The outlook compares against an analyst estimate of $416.263 million.
7 days agoIovance Biotherapeutics grants 111,615 stock options to new employees
Iovance Biotherapeutics granted inducement stock options for 111,615 shares to 21 new non-executive employees on October 15, 2026. Each option has an exercise price of $14.72, equal to the closing stock price on the grant date. Awards vest over three years: one-third after one year, with the remainder in eight quarterly installments. Grants were made under the Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
27 days agoIovance Biotherapeutics Q2FY26 Results: Revenue up 66% YoY to $99.3M
Record Q2FY26 revenue of $99.3 million, up 66% YoY and 39% QoQ. Gross margin expanded to an all-time high of 56%, driven by manufacturing efficiencies. Amtagvi revenue reached ~$91 million, exceeding guidance range of $79-$81 million. Cash position of $304 million expected to fund operations into H2 2028. Full-year revenue guidance review underway, with updates planned for Q3.
1mo agoGoldman Sachs reinstates Buy on Iovance Biotherapeutics with $15 target
Goldman Sachs reinstates Buy rating on Iovance Biotherapeutics. Analyst Andrea Newkirk assigns a $15 price target. The move reflects updated coverage on the NASDAQ-listed stock.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Iovance Biotherapeutics is now worth
$ 32.45
Resulting in a loss of
$ 67.55 (67.55%)
Note: Past profits do not guarantee future returns.
